June 13, 2024 02:54 PM EDTUpdated June 14, 10:26 AM

Stakeholders weigh in on potential reforms to FDA advisory committee process

Lia DeGroot

The FDA on Thursday heard feedback from a slew of stakeholders on potential upcoming changes to the advisory committee process — and the reviews were mixed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Stakeholders weigh in on potential reforms to FDA advisory committee process

Lia DeGroot

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Stake­hold­ers weigh in on po­ten­tial re­forms to FDA ad­vi­so­ry com­mit­tee process

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Stakeholders weigh in on potential reforms to FDA advisory committee process